Skip to main content
Erschienen in: International Journal of Clinical Oncology 6/2010

01.12.2010 | Case Report

Diagnosis of primary versus metastatic ovarian adenocarcinoma using p53 gene mutation analysis

verfasst von: Tomoki Yamano, Eiichi Morii, Isao Arai, Toshiaki Takada, Ken Kubota, Masahiko Sato, Takaaki Inoue, Yoshihiro Okada, Takahiko Hara, Katsuyuki Aozasa

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Distinguishing primary ovarian cancer from metastatic colorectal cancer is often difficult by a conventional pathological examination alone. We assessed the usefulness of p53 gene mutation analysis for the differential diagnosis of ovarian adenocarcinoma. A 66-year-old woman suffered multiple organ metastases, including the liver, para-aortic lymph node, and right ovary, following an operation for advanced sigmoid colon cancer. She underwent ovarian resection after effective chemotherapy against the liver and para-aortic lymph node cancer. Histological analysis suggested primary ovarian cancer. Therefore, we applied p53 gene mutation analysis for the differential diagnosis of primary versus metastatic ovarian cancer from sigmoid colon cancer. The direct sequence of the p53 gene demonstrated the same gene mutation in codon 211 (ACT to ATT) in both the sigmoid colon and ovarian cancers. According to the International Agency for Research on Cancer TP53 mutation database, this type of p53 mutation in colorectal cancer and ovarian cancer is 0.13% (5/3,693) and 0% (0/1,494), respectively. Therefore, we determined that the ovarian tumor was metastatic. Although p53 gene mutation analysis has been applied in some cases, this modality is very useful for the differential diagnosis of primary and metastatic cancer.
Literatur
1.
Zurück zum Zitat Yada-Hashimoto N, Yamamoto T, Kamiura S et al (2003) Metastatic ovarian tumors: a review of 64 cases. Gynecol Oncol 89:314–317PubMedCrossRef Yada-Hashimoto N, Yamamoto T, Kamiura S et al (2003) Metastatic ovarian tumors: a review of 64 cases. Gynecol Oncol 89:314–317PubMedCrossRef
2.
Zurück zum Zitat Turan T, Aykan B, Koc S et al (2006) Analysis of metastatic ovarian tumors from extragenital primary sites. Tumori 92:491–495PubMed Turan T, Aykan B, Koc S et al (2006) Analysis of metastatic ovarian tumors from extragenital primary sites. Tumori 92:491–495PubMed
3.
Zurück zum Zitat Salamalekis E, Bakas P, Sykiotis K et al (2004) Outcome of patients with ovarian metastatic tumors. Report of 83 cases and review. Eur J Gynaecol Oncol 25:713–715PubMed Salamalekis E, Bakas P, Sykiotis K et al (2004) Outcome of patients with ovarian metastatic tumors. Report of 83 cases and review. Eur J Gynaecol Oncol 25:713–715PubMed
4.
Zurück zum Zitat Hanna NN, Cohen AM (2004) Ovarian neoplasms in patients with colorectal cancer: understanding the role of prophylactic oophorectomy. Clin Colorectal Cancer 3:215–222PubMedCrossRef Hanna NN, Cohen AM (2004) Ovarian neoplasms in patients with colorectal cancer: understanding the role of prophylactic oophorectomy. Clin Colorectal Cancer 3:215–222PubMedCrossRef
5.
Zurück zum Zitat Huang PP, Weber TK, Mendoza C et al (1998) Long-term survival in patients with ovarian metastases from colorectal carcinoma. Ann Surg Oncol 5:695–698PubMedCrossRef Huang PP, Weber TK, Mendoza C et al (1998) Long-term survival in patients with ovarian metastases from colorectal carcinoma. Ann Surg Oncol 5:695–698PubMedCrossRef
6.
Zurück zum Zitat Abu-Rustum N, Barakat RR, Curtin JP (1997) Ovarian and uterine disease in women with colorectal cancer. Obstet Gynecol 89:85–87PubMedCrossRef Abu-Rustum N, Barakat RR, Curtin JP (1997) Ovarian and uterine disease in women with colorectal cancer. Obstet Gynecol 89:85–87PubMedCrossRef
7.
Zurück zum Zitat Grothey A, Sargent D, Goldberg RM et al (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214PubMedCrossRef Grothey A, Sargent D, Goldberg RM et al (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214PubMedCrossRef
8.
Zurück zum Zitat Yemelyanova AV, Vang R, Judson K et al (2008) Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol 32:128–138PubMedCrossRef Yemelyanova AV, Vang R, Judson K et al (2008) Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol 32:128–138PubMedCrossRef
9.
Zurück zum Zitat Cathro HP, Stoler MH (2002) Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol 117:944–951PubMedCrossRef Cathro HP, Stoler MH (2002) Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol 117:944–951PubMedCrossRef
10.
Zurück zum Zitat Park SY, Kim HS, Hong EK et al (2002) Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 33:1078–1085PubMedCrossRef Park SY, Kim HS, Hong EK et al (2002) Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 33:1078–1085PubMedCrossRef
11.
Zurück zum Zitat Logani S, Oliva E, Arnell PM et al (2005) Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol 18:19–25PubMedCrossRef Logani S, Oliva E, Arnell PM et al (2005) Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol 18:19–25PubMedCrossRef
12.
Zurück zum Zitat Vang R, Gown AM, Wu LS et al (2006) Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 19:1421–1428PubMedCrossRef Vang R, Gown AM, Wu LS et al (2006) Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 19:1421–1428PubMedCrossRef
13.
Zurück zum Zitat Oda T, Tsuda H, Scarpa A et al (1992) Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res 52:3674–3678PubMed Oda T, Tsuda H, Scarpa A et al (1992) Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res 52:3674–3678PubMed
14.
Zurück zum Zitat Noguchi M, Maezawa N, Nakanishi Y et al (1993) Application of the p53 gene mutation pattern for differential diagnosis of primary versus metastatic lung carcinomas. Mol Pathol 2:29–35 Noguchi M, Maezawa N, Nakanishi Y et al (1993) Application of the p53 gene mutation pattern for differential diagnosis of primary versus metastatic lung carcinomas. Mol Pathol 2:29–35
15.
Zurück zum Zitat Nakazato Y, Tanaka R, Seki E et al (2008) Differential diagnosis of primary versus metastatic pulmonary adenocarcinomas using gene mutation analyses: a case report. J Thorac Oncol 3:931–934PubMedCrossRef Nakazato Y, Tanaka R, Seki E et al (2008) Differential diagnosis of primary versus metastatic pulmonary adenocarcinomas using gene mutation analyses: a case report. J Thorac Oncol 3:931–934PubMedCrossRef
16.
Zurück zum Zitat Mok CH, Tsao SW, Knapp RC et al (1992) Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res 52:5119–5122PubMed Mok CH, Tsao SW, Knapp RC et al (1992) Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res 52:5119–5122PubMed
17.
Zurück zum Zitat Russo A, Bazan V, Iacopetta B et al (2005) The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23:7518–7528PubMedCrossRef Russo A, Bazan V, Iacopetta B et al (2005) The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23:7518–7528PubMedCrossRef
18.
Zurück zum Zitat Khan ZA, Jonas SK, Le-Marer N et al (2000) P53 mutations in primary and metastatic tumors and circulating tumor cells from colorectal carcinoma patients. Clin Cancer Res 6:3499–3504PubMed Khan ZA, Jonas SK, Le-Marer N et al (2000) P53 mutations in primary and metastatic tumors and circulating tumor cells from colorectal carcinoma patients. Clin Cancer Res 6:3499–3504PubMed
19.
Zurück zum Zitat Albanese I, Scibetta AG, Migliavacca M et al (2004) Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 325:784–791PubMedCrossRef Albanese I, Scibetta AG, Migliavacca M et al (2004) Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 325:784–791PubMedCrossRef
Metadaten
Titel
Diagnosis of primary versus metastatic ovarian adenocarcinoma using p53 gene mutation analysis
verfasst von
Tomoki Yamano
Eiichi Morii
Isao Arai
Toshiaki Takada
Ken Kubota
Masahiko Sato
Takaaki Inoue
Yoshihiro Okada
Takahiko Hara
Katsuyuki Aozasa
Publikationsdatum
01.12.2010
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 6/2010
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-010-0096-z

Weitere Artikel der Ausgabe 6/2010

International Journal of Clinical Oncology 6/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.